AbbVie has announced that its Phase III TEMPLE study, which compared atogepant to topiramate for migraine, has met its ...

BioOrbit CEO Dr Katie King said that pre-clinical studies of the crystals produced in space could start as early as 2026.

Biogen has commenced dosing in the Phase III BRAVE study of omaveloxolone in children of two-< 16 years of age with ...

MSD and Daiichi Sankyo have announced first subject dosing in the IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan ...

A report from the CDC across the US has found that ASD rates in children aged between 4-8 years were higher in 2022 than in ...

NHS England chair Penny Dash shared her views on European healthcare during a fireside discussion at HLTH Europe in Amsterdam ...

Oncology clinical trials are complex and costly, making successful setup critical. Challenges include long timelines and ...

Lyell Immunopharma has reported new clinical data from the Phase I/II clinical trial of CAR T-cell product candidate, LYL314.

Ventyx Biosciences has reported encouraging top-line outcomes from its Phase IIa trial of VTX3232 for early-stage Parkinson's ...

Clarametyx Biosciences has received approval from the Independent DMC to progress its Phase Ib/IIa trial of CMTX-101 ...

The US FDA has approved Ocugen’s IND amendment to commence a Phase II/III pivotal confirmatory study of OCU410ST.

This space already includes two approved CAR T-cell therapies: Johnson & Johnson/Legend’s Carvykti and Bristol Myers Squibb’s ...